1. Home
  2. ACR vs SGMT Comparison

ACR vs SGMT Comparison

Compare ACR & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACR

ACRES Commercial Realty Corp.

HOLD

Current Price

$18.50

Market Cap

146.1M

Sector

Real Estate

ML Signal

HOLD

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$7.06

Market Cap

169.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACR
SGMT
Founded
2005
2006
Country
United States
United States
Employees
4
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
146.1M
169.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ACR
SGMT
Price
$18.50
$7.06
Analyst Decision
Buy
Strong Buy
Analyst Count
1
8
Target Price
$24.50
$26.13
AVG Volume (30 Days)
40.5K
781.4K
Earning Date
04-30-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.59
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.61
$4.50
52 Week High
$24.61
$11.41

Technical Indicators

Market Signals
Indicator
ACR
SGMT
Relative Strength Index (RSI) 47.92 55.64
Support Level $17.56 $6.26
Resistance Level $19.47 $7.20
Average True Range (ATR) 0.84 0.33
MACD 0.09 0.05
Stochastic Oscillator 75.96 76.82

Price Performance

Historical Comparison
ACR
SGMT

About ACR ACRES Commercial Realty Corp.

ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding, and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralized debt obligations, and private equity investments mainly issued by financial institutions.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: